{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:55:13Z","timestamp":1791888913425,"version":"4.3.4"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","immunology.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.iac.2017.01.005","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T20:46:21Z","timestamp":1488401181000},"page":"283-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Biologic Therapies for Autoimmune and Connective Tissue Diseases"],"prefix":"10.1016","volume":"37","author":[{"given":"Rachel M.","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2017.01.005_bib1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2017.01.005_bib2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib3","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/rheumatology\/keh297","article-title":"Remission in rheumatoid arthritis: agreement of the Disease Active Score (DAS28) with the ARA preliminary remission criteria","volume":"43","author":"Fransen","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.iac.2017.01.005_bib4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"42","key":"10.1016\/j.iac.2017.01.005_bib5","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta10420","article-title":"A\u00a0systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.iac.2017.01.005_bib6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":"Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.iac.2017.01.005_bib7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.autrev.2009.12.010","article-title":"Switching TNF-alpha antagonist in rheumatoid arthritis: the experience of the Lorhen registry","volume":"9","author":"Caporali","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.iac.2017.01.005_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"issue":"2","key":"10.1016\/j.iac.2017.01.005_bib9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/RHU.0000000000000358","article-title":"Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis","volume":"22","author":"Santos-Moreno","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.iac.2017.01.005_bib10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A\u00a0comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry","volume":"71","author":"Greenberg","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib11","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.iac.2017.01.005_bib12","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iac.2017.01.005_bib14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.iac.2017.01.005_bib15","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2017.01.005_bib16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.iac.2017.01.005_bib18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","article-title":"Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib19","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"66","author":"Kivitz","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.iac.2017.01.005_bib20","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/acr.22598","article-title":"Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis","volume":"67","author":"Ogata","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.iac.2017.01.005_bib21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/rheumatology\/ket018","article-title":"Subcutaneous abatacept for the treatment of rheumatoid arthritis","volume":"52","author":"Schiff","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.iac.2017.01.005_bib22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3899\/jrheum.130112","article-title":"Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial","volume":"44","author":"Genovese","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.iac.2017.01.005_bib23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.iac.2017.01.005_bib24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study","volume":"65","author":"Nash","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.iac.2017.01.005_bib25","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.iac.2017.01.005_bib26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3899\/jrheum.120573","article-title":"Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5 year data from the REFLEX study","volume":"39","author":"Keystone","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.iac.2017.01.005_bib28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.iac.2017.01.005_bib29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.iac.2017.01.005_bib30","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.iac.2017.01.005_bib31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-016-0951-z","article-title":"Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration","volume":"18","author":"Chatzidionysiou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.iac.2017.01.005_bib32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3904\/kjim.2014.29.5.656","article-title":"Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials","volume":"29","author":"Song","year":"2014","journal-title":"Korean J Intern Med"},{"issue":"7","key":"10.1016\/j.iac.2017.01.005_bib33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iac.2017.01.005_bib34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematous: a randomized, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.iac.2017.01.005_bib35","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib36","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.iac.2017.01.005_bib37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematous: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.iac.2017.01.005_bib38","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: the randomized double-blind phase II\/III Systemic Lupus Erythematosus Evaluation of Rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2017.01.005_bib40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","article-title":"Off-label use of rituximab in systemic lupus erythematosus: a systemic review","volume":"29","author":"Murray","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.iac.2017.01.005_bib41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematous: a systemic review","volume":"44","author":"Cobo-Ibanez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.iac.2017.01.005_bib42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11926-016-0589-5","article-title":"Update on biological therapy for systemic lupus erythematosus","volume":"18","author":"Lobo Borba","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib43","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept and cyclophosphamide efficacy and safety study","volume":"66","author":"Askanase","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib44","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete remission support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.iac.2017.01.005_bib45","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematous","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2017.01.005_bib46","unstructured":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01714817. Accessed June 29, 2016."},{"issue":"7","key":"10.1016\/j.iac.2017.01.005_bib47","first-page":"1318","article-title":"Rituximab in treatment of inflammatory myopathies: a review","volume":"55","author":"Fasano","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.iac.2017.01.005_bib48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.iac.2017.01.005_bib49","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.iac.2017.01.005_bib50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A\u00a0randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"The Muscle Study Group","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.iac.2017.01.005_bib51","doi-asserted-by":"publisher","first-page":"179180","DOI":"10.1155\/2014\/179180","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"2014","author":"Brunasso","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.iac.2017.01.005_bib52","series-title":"Abatacept for the treatment of refractory juvenile dermatomyositis. In: ClinicalTrials.gov [Internet]","author":"George Washington University","year":"2000"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","article-title":"Modern therapies for idiopathic inflammatory myopathies: role of biologics","volume":"52","author":"Moghadam-Kia","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.iac.2017.01.005_bib54","series-title":"Tocilizumab in the treatment of refractory polymyositis and dermatomyositis. In: ClinicalTrials.gov [Internet]","author":"University of Pittsburgh","year":"2000"},{"issue":"12","key":"10.1016\/j.iac.2017.01.005_bib55","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.iac.2017.01.005_bib56","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.iac.2017.01.005_bib57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.iac.2017.01.005_bib58","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib59","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systemic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"issue":"26","key":"10.1016\/j.iac.2017.01.005_bib60","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an IL-17A inhibitor in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.005_bib61","first-page":"883","article-title":"Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systemic review and metaanalysis of randomized control trials","volume":"35","author":"Saad","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.iac.2017.01.005_bib62","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3899\/jrheum.151404","article-title":"Assessment of response to treatment, remission and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors","volume":"43","author":"Lubrano","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.iac.2017.01.005_bib63","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2017.01.005_bib64","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Richlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.iac.2017.01.005_bib65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomized phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iac.2017.01.005_bib66","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2017.01.005_bib67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide in ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.005_bib68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2017.01.005_bib69","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of randomized trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iac.2017.01.005_bib70","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.iac.2017.01.005_bib71","doi-asserted-by":"publisher","first-page":"e115026","DOI":"10.1371\/journal.pone.0115026","article-title":"The role of biological agents in the management of large vessel vasculitis (LVV): a systemic review and meta-analysis","volume":"9","author":"Osman","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.iac.2017.01.005_bib72","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3899\/jrheum.151252","article-title":"Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients","volume":"43","author":"Regent","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.iac.2017.01.005_bib73","article-title":"Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis [abstract]","volume":"67","author":"Tuckwell","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.iac.2017.01.005_bib74","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A\u00a0pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res"},{"key":"10.1016\/j.iac.2017.01.005_bib75","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11926-013-0398-z","article-title":"Anti-interleukin-1 therapy in the management of gout","volume":"16","author":"Schlesinger","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.iac.2017.01.005_bib76","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.iac.2017.01.005_bib77","author":"Eli Lily and Company","year":"2000"},{"key":"10.1016\/j.iac.2017.01.005_bib78","unstructured":"FDA approved drug products. US Food and Drug Administration Web site. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Search_Drug_Name Last updated: daily. Accessed June 15, 2016."}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985611730005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985611730005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T06:36:43Z","timestamp":1568875003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985611730005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S088985611730005X"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.005","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Therapies for Autoimmune and Connective Tissue Diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2017.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}